Literature DB >> 9287995

Uroguanylin and guanylin: distinct but overlapping patterns of messenger RNA expression in mouse intestine.

T L Whitaker1, D P Witte, M C Scott, M B Cohen.   

Abstract

BACKGROUND & AIMS: Uroguanylin and guanylin, endogenous ligands of the guanylate cyclase C receptor, are presumed to mediate fluid and electrolyte secretion in the intestine. The aim of this study was to characterize the expression patterns of uroguanylin and guanylin messenger RNA (mRNA) in the mouse intestine.
METHODS: A mouse uroguanylin complementary DNA was amplified from a partial genomic clone, and Northern analyses and in situ hybridization were performed to localize guanylin and uroguanylin mRNA along the duodenal-colonic and crypt-villus axes.
RESULTS: Uroguanylin mRNA was expressed throughout the mouse intestine and also in the kidney. Signal intensity was greatest in the small intestine for uroguanylin and in the distal small intestine and colon for guanylin. In situ hybridization showed uroguanylin mRNA localized predominantly in intestinal villi and the corticomedullary junction of the kidney, whereas guanylin mRNA was localized in both crypts and villi in the small intestine and to superficial epithelial cells in the colon.
CONCLUSIONS: Mouse uroguanylin mRNA expression is discrete from guanylin expression in the intestine. The patterns of distribution in the intestine and the known pH optima of these ligands suggest a complementary role for these secretagogues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287995     DOI: 10.1016/s0016-5085(97)70197-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation.

Authors:  Kris A Steinbrecher; Steve A Wowk; Jeffrey A Rudolph; David P Witte; Mitchell B Cohen
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  E. coli heat-stable enterotoxin and guanylyl cyclase C: new functions and unsuspected actions.

Authors:  Ralph A Giannella; Elizabeth A Mann
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

3.  Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.

Authors:  Giovanni M Pitari; Jieru E Lin; Fawad J Shah; Wilhelm J Lubbe; David S Zuzga; Peng Li; Stephanie Schulz; Scott A Waldman
Journal:  Carcinogenesis       Date:  2008-06-19       Impact factor: 4.944

4.  Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load.

Authors:  John N Lorenz; Michelle Nieman; Jenine Sabo; L Philip Sanford; Jennifer A Hawkins; Noeet Elitsur; Lara R Gawenis; Lane L Clarke; Mitchell B Cohen
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 5.  Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide.

Authors:  Siegfried W B Yu; Satish S C Rao
Journal:  Therap Adv Gastroenterol       Date:  2014-09       Impact factor: 4.409

6.  Occurrence and localization of uroguanylin in the aging human prostate.

Authors:  Caroline Maake; Franziska Auf der Maur; Katarina Jovanovic; Manfred Reinecke; Dieter Hauri; Hubert John
Journal:  Histochem Cell Biol       Date:  2002-12-21       Impact factor: 4.304

7.  Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide.

Authors:  Nicholas G Moss; Robert C Fellner; Xun Qian; Sharon J Yu; Zhiping Li; Masamitsu Nakazato; Michael F Goy
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

Review 8.  Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.

Authors:  Erik S Blomain; Dante J Merlino; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Mol Pharmacol       Date:  2016-06-01       Impact factor: 4.436

Review 9.  Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.

Authors:  Giovanni M Pitari
Journal:  Drug Des Devel Ther       Date:  2013-04-19       Impact factor: 4.162

Review 10.  Current understanding of guanylin peptides actions.

Authors:  Aleksandra Sindic
Journal:  ISRN Nephrol       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.